Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence

Metabolism: Clinical and Experimental

Volumn 96, Issue , 2019, Pages 92-100

  Katsiki, Niki ^a   Dimitriadis, George ^b   Hahalis, George ^c   Papanas, Nikolaos ^d   Tentolouris, Nikolaos ^e   Triposkiadis, Filippos ^f   Tsimihodimos, Vasilios ^g   Tsioufis, Costas ^e   Mikhailidis, Dimitri P ^h   Mantzoros, Christos ⁱ  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amputation; Canagliflozin; Cardiovascular risk; Dapagliflozin; Empagliflozin; Renal outcomes; Sodium glucose co transporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

AMPUTATION; CARDIOVASCULAR RISK; DRUG USE; EPICARDIAL FAT; HUMAN; INTRA-ABDOMINAL FAT; NOTE; PATIENT SAFETY; PERIRENAL FAT; PERIVASCULAR ADIPOSE TISSUE; PRIORITY JOURNAL; RISK ASSESSMENT; ADVERSE EVENT; COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS;

AMPUTATION; BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85063099448     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2019.04.008     Document Type: Note

References (99)

1. Steen, O., Goldenberg, R.M., The role of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Can J Diabetes 41:5 (2017), 517–523.
2. Wilding, J.P., The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10 (2014), 1228–1237.
3. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. Curr Med Res Opin 32:9 (2016), 1513–1514.
4. Katsiki, N., Papanas, N., Mikhailidis, D.P., Dapagliflozin: more than just another oral glucose-lowering agent?. Expert Opin Investig Drugs 19:12 (2010), 1581–1589.
5. Mamakou, V., Eleftheriadou, I., Katsiki, N., Makrilakis, K., Tsioufis, K., Tentolouris, N., Antidiabetic drugs as antihypertensives: new data on the horizon. Curr Vasc Pharmacol 16:1 (2017), 70–78.
6. Upadhyay, J., Polyzos, S.A., Perakakis, N., Thakkar, B., Paschou, S.A., Katsiki, N., et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism 78 (2018), 13–42.
7. Yaribeygi, H., Butler, A.E., Atkin, S.L., Katsiki, N., Sahebkar, A., Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol 234:1 (2018), 223–230.
8. Yaribeygi, H., Katsiki, N., Butler, A.E., Sahebkar, A., Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today 24 (2019), 256–262.
9. Verma, S., McMurray, J.J.V., SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:10 (2018), 2108–2117.
10. Thomas, M.C., Cherney, D.Z.I., The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:10 (2018), 2098–2107.
11. Garvey, W.T., Van Gaal, L., Leiter, L.A., Vijapurkar, U., List, J., Cuddihy, R., et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 85 (2018), 32–37.
12. Katsiki, N., Mikhailidis, D.P., Theodorakis, M.J., Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management. Curr Pharm Des 23:10 (2017), 1522–1532.
13. Esterline, R.L., Vaag, A., Oscarsson, J., Vora, J., Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?. Eur J Endocrinol 178:4 (2018), R113–R125.
14. Sumida, Y., Yoneda, M., Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53:3 (2018), 362–376.
15. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications 31:3 (2017), 521–522.
16. Athyros, V.G., Katsiki, N., Karagiannis, A., Editorial: can glucagon like peptide 1 (GLP1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes?. Curr Vasc Pharmacol 14:6 (2016), 494–497.
17. Katsiki, N., Imprialos, K., Vlachopoulos, C., Editorial: arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: links with cardiovascular risk and effects of drug treatment. Curr Vasc Pharmacol 16:4 (2018), 401–404.
18. Katsiki, N., Perez-Martinez, P., Anagnostis, P., Mikhailidis, D.P., Karagiannis, A., Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?. Curr Vasc Pharmacol 16:3 (2018), 219–227.
19. Lonardo, A., Sookoian, S., Pirola, C.J., Targher, G., Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65:8 (2016), 1136–1150.
20. Reccia, I., Kumar, J., Akladios, C., Virdis, F., Pai, M., Habib, N., et al. Non-alcoholic fatty liver disease: a sign of systemic disease. Metabolism 72 (2017), 94–108.
21. Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65:8 (2016), 1109–1123.
22. Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr, 9, 2017, 78.
23. Fukuda, T., Bouchi, R., Terashima, M., Sasahara, Y., Asakawa, M., Takeuchi, T., et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8:4 (2017), 851–861.
24. Bouchi, R., Terashima, M., Sasahara, Y., Asakawa, M., Fukuda, T., Takeuchi, T., et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol, 16(1), 2017, 32.
25. Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol, 17(1), 2018, 6.
26. Díaz-Rodríguez, E., Agra, R.M., Fernández, Á.L., Adrio, B., García-Caballero, T., González-Juanatey, J.R., et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 114:2 (2018), 336–346.
27. Guglielmi, V., Sbraccia, P., Epicardial adipose tissue: at the heart of the obesity complications. Acta Diabetol 54:9 (2017), 805–812.
28. Xourgia, E., Papazafiropoulou, A., Melidonis, A., Effects of antidiabetic drugs on epicardial fat. World J Diabetes 9:9 (2018), 141–148.
29. Lazaros, G., Antonopoulos, A., Antoniades, C., Tousoulis, D., The role of epicardial fat in pericardial diseases. Curr Cardiol Rep, 20(6), 2018, 40.
30. Katsiki, N., Mikhailidis, D.P., Wierzbicki, A.S., Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 28:4 (2013), 458–463.
31. Katsiki, N., Mikhailidis, D.P., Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?. Anatol J Cardiol 17:1 (2017), 64–65.
32. Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?. Curr Vasc Pharmacol 14:5 (2016), 432–441.
33. Katsiki, N., Purrello, F., Tsioufis, C., Mikhailidis, D.P., Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother 18:12 (2017), 1243–1260.
34. Wanner, C., Marx, N., SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61:10 (2018), 2134–2139.
35. Heerspink, H.J.L., Kosiborod, M., Inzucchi, S.E., Cherney, D.Z.I., Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94:1 (2018), 26–39.
36. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al., EMPA-REG OUTCOME Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
37. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al., EMPA-REG OUTCOME Investigators, Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:4 (2016), 323–334.
38. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al., CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:7 (2017), 644–657.
39. Mundell, B.F., Luetmer, M.T., Kremers, H.M., Visscher, S., Hoppe, K.M., Kaufman, K.R., The risk of major cardiovascular events for adults with transfemoral amputation. J Neuroeng Rehabil, 15(Suppl. 1), 2018, 58.
40. Fortington, L.V., Geertzen, J.H., van Netten, J.J., Postema, K., Rommers, G.M., Dijkstra, P.U., Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg 46:1 (2013), 124–131.
41. Grzebień, A., Chabowski, M., Malinowski, M., Uchmanowicz, I., Milan, M., Janczak, D., Analysis of selected factors determining quality of life in patients after lower limb amputation- a review article. Pol Przegl Chir 89:2 (2017), 57–61.
42. Paraskevas, K.I., Baker, D.M., Pompella, A., Mikhailidis, D.P., Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview. Ann Vasc Surg 22:3 (2008), 481–491.
43. Inzucchi, S.E., Iliev, H., Pfarr, E., Zinman, B., Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:1 (2018), e4–e5.
44. Kohler, S., Zeller, C., Iliev, H., Kaspers, S., Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34:7 (2017), 1707–1726.
45. Verma, S., Mazer, C.D., Al-Omran, M., Inzucchi, S.E., Fitchett, D., Hehnke, U., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137:4 (2018), 405–407.
46. Jabbour, S., Seufert, J., Scheen, A., Bailey, C.J., Karup, C., Langkilde, A.M., Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20:3 (2018), 620–628.
47. Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al., DECLARE–TIMI 58 Investigators, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380 (2019), 347–357.
48. Khouri, C., Cracowski, J.L., Roustit, M., SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?. Diabetes Obes Metab 20:6 (2018), 1531–1534.
49. Bonaca, M.P., Beckman, J.A., Sodium glucose cotransporter 2 inhibitors and amputation risk: Achilles' heel or opportunity for discovery?. Circulation 137:14 (2018), 1460–1462.
50. Tanaka, A., Node, K., Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. Cardiovasc Diabetol, 16, 2017, 129.
51. Erkens, J.A., Klungel, O.H., Stolk, R.P., Spoelstra, J.A., Grobbee, D.E., Leufkens, H.G., Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Saf 13:3 (2004), 139–146.
52. https://easddistribute.m-anage.com/from.storage?image=4iBH9mRQm1kfeEHULC2CxoQ5s0zIQheog0-Vnk2yQfy65SNcsyRuTUA5eLDkP_ix0 [Last accessed 19 January 2019].
53. Dietrich, I., Braga, G.A., de Melo, F.G., da Costa Silva Silva, A.C.C., The diabetic foot as a proxy for cardiovascular events and mortality review. Curr Atheroscler Rep, 19(11), 2017, 44.
54. Ciocan, R.A., Bolboacă, S.D., Rădulescu, Ş., Stancu, B., Ciocan, A., Gherman, C.D., Demographic and comorbidity pattern of patients with critical limb ischemia. Folia Med (Plovdiv) 59:1 (2017), 14–22.
55. Callaghan, B.C., Feldman, E., Liu, J., Kerber, K., Pop-Busui, R., Moffet, H., et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 34:3 (2011), 635–640.
56. Li, B., Wang, Y., Ye, Z., Yang, H., Cui, X., Wang, Z., et al. Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Pharm Pharm Sci 21:1 (2018), 222–235.
57. Xiong, W., Xiao, M.Y., Zhang, M., Chang, F., Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Medicine (Baltimore), 95(48), 2016, e5473.
58. Hattori, S., Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance. J Diabetes Investig 9:4 (2018), 870–874.
59. Hinnen, D., Short commentary on empagliflozin and its potential clinical impact. Ther Adv Endocrinol Metab 6:2 (2015), 68–81.
60. Mazidi, M., Rezaie, P., Gao, H.K., Kengne, A.P., Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc, 6(6), 2017.
61. Brown, R.E., Gupta, N., Aronson, R., Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. Diabetes Technol Ther 19:11 (2017), 685–691.
62. Jabbour, S.A., Frías, J.P., Guja, C., Hardy, E., Ahmed, A., Öhman, P., Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab 20:6 (2018), 1515–1519.
63. Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Diabetes, bilirubin and amputations: is there a link?. Diabetologia 56:4 (2013), 683–685.
64. Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N., et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab 17:2 (2015), 188–197.
65. Leiter, L.A., Forst, T., Polidori, D., Balis, D.A., Xie, J., Sha, S., Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42:1 (2016), 25–32.
66. Ramirez, A.J., Sanchez, M.J., Sanchez, R.A., Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. J Hypertens 37 (2019), 636–642.
67. Chung, J., Timaran, D.A., Modrall, J.G., Ahn, C., Timaran, C.H., Kirkwood, M.L., et al. Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia. J Vasc Surg 58:4 (2013), 972–980.
68. Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8 (2014), 1335–1380.
69. Hawley, S.A., Ford, R.J., Smith, B.K., Gowans, G.J., Mancini, S.J., Pitt, R.D., et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65:9 (2016), 2784–2794.
70. Alnaeb, M.E., Thompson, C.S., Seifalian, A.M., Hamilton, G., Mikhailidis, D.P., Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study. In Vivo 21:6 (2007), 1069–1074.
71. Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J.M., et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1:2 (2010), 57–92.
72. Lee, W.S., Kanai, Y., Wells, R.G., Hediger, M.A., The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269:16 (1994), 12032–12039.
73. https://www.boehringer-ingelheim.ca/sites/ca/files/documents/jardiancepmen.pdf [Last accessed 19 January 2019].
74. Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S.C., Boulton, D.W., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53:1 (2014), 17–27.
75. Devineni, D., Polidori, D., Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet 54:10 (2015), 1027–1041.
76. https://www.fda.gov/Drugs/DrugSafety/ucm500965.htm [Last accessed 19 January 2019].
77. https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm [Last accessed 19 January 2019].
78. http://www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp%26mid%3DWC0b01ac05805c516f [Last accessed 19 January 2019].
79. Scheen, A.J., Does lower limb amputation concern all SGLT2 inhibitors?. Nat Rev Endocrinol 14:6 (2018), 326–328.
80. Fadini, G.P., Avogaro, A., SGLT2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol 5:9 (2017), 680–681.
81. Sung, J., Padmanabhan, S., Gurung, S., Inglis, S., Vicaretti, M., Begg, L., et al. SGLT2 inhibitors and amputation risk: real-world data from a diabetes foot wound clinic. J Clin Transl Endocrinol 13 (2018), 46–47.
82. Li, D., Yang, J.Y., Wang, T., Shen, S., Tang, H., Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab 44:5 (2018), 410–414.
83. Udell, J.A., Yuan, Z., Rush, T., Sicignano, N.M., Galitz, M., Rosenthal, N., Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation 137:14 (2018), 1450–1459.
84. Yuan, Z., DeFalco, F.J., Ryan, P.B., Schuemie, M.J., Stang, P.E., Berlin, J.A., et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes Metab 20:3 (2018), 582–589.
85. Ryan, P.B., Buse, J.B., Schuemie, M.J., DeFalco, F., Yuan, Z., Stang, P.E., et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20:11 (2018), 2585–2597.
86. Ryan, P.B., Rosenthal, N., Comment on "comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D)". Diabetes Obes Metab 21:2 (2019 Feb), 444–445.
87. Chang, H.Y., Singh, S., Mansour, O., Baksh, S., Alexander, G.C., Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 178:9 (2018), 1190–1198.
88. Hsu, C.Y., Chen, Y.T., Su, Y.W., Chang, C.C., Huang, P.H., Lin, S.J., Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 102:7 (2017), 2373–2381.
89. Sohn, M.W., Meadows, J.L., Oh, E.H., Budiman-Mak, E., Lee, T.A., Stone, N.J., et al. Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg 58:6 (2013), 1578–1585.
90. Katsiki, N., Giannoukas, A.D., Athyros, V.G., Mikhailidis, D.P., Lipid-lowering treatment in peripheral artery disease. Curr Opin Pharmacol 39 (2018), 19–26.
91. Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.M., Franzén, S., et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register-based cohort study. BMJ, 363, 2018, k4365.
92. Adimadhyam, S., Lee, T.A., Calip, G.S., Smith Marsh, D.E., Layden, B.T., Schumock, G.T., Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study. Diabetes Obes Metab 20:12 (2018), 2792–2799.
93. Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21:5 (2015), 512–517.
94. Kalra, S., Gupta, Y., Patil, S., Sodium-glucose cotransporter-2 inhibition and the insulin: glucagon ratio: unexplored dimensions. Indian J Endocrinol Metab 19:3 (2015), 426–429.
95. Campbell, J.E., Drucker, D.J., Islet α cells and glucagon—critical regulators of energy homeostasis. Nat Rev Endocrinol 11:6 (2015), 329–338.
96. Matthews, D.R., Li, Q., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. Diabetologia, 2019 [Epub ahead of print].
97. Nakamura, I., Maegawa, H., Tobe, K., Tabuchi, H., Uno, S., Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother 19:3 (2018), 189–201.
98. Terauchi, Y., Tamura, M., Senda, M., Gunji, R., Kaku, K., Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicentre, randomized, double-blind, open-label extension, phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab 20:5 (2018), 1176–1185.
99. Miller, S., Krumins, T., Zhou, H., Huyck, S., Johnson, J., Golm, G., et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther 9:1 (2018), 253–268.